“We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing so.” Seres Therapeutics CEO Eric Shaff explains how the company is building on its experience developing VOWST, the first-ever FDA-approved oral life biotherapeutic, as it pioneers new therapies like SER-155 to address unmet need in in allo-HSCT. More from Flagship @ JPM2025 here.
Related Companies
- Seres Therapeutics Founded: 2011
